Loading company…
Surf Bio develops surfactant-based therapeutic technologies, including ultra-rapid insulin.
Founded in 2021 and based in Palo Alto, Surf Bio develops surfactant-based therapies for diabetes, oncology, infectious diseases, and gene therapy. It is developing ultra-rapid insulin and a polymer-based drug delivery platform. In March 2022, the company raised USD 16 million in seed funding co-led by Breakout Labs and Perceptive Advisors.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in